 MIAMI, June 28, 2021 GLOBE NEWSWIRE -- Veru Inc. NASDAQ: VERU, an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancers, today announced updated clinical results from the ongoing Phase 1b2 clinical study of sabizabulin VERU-111, an oral cytoskeleton disruptor being evaluated for the treatment of metastatic castration resistant prostate cancer in men who progressed on an androgen receptor targeting agent, were accepted for presentation at the European Association of Urology 36th Annual Congress. The Congress is being held virtually from July 8-12, 2021. 